(Q42933669)

English

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection

scientific article published on 18 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection (English)

1 reference

Europe PubMed Central

11 November 2017

Giuseppe Remuzzi

7

1 reference

Europe PubMed Central

11 November 2017

Lorenzo Arnaboldi

object named as

Lorenzo Arnaboldi

5

0 references

object named as

Ariela Benigni

6

0 references

2

object named as

Daniela Corna

1 reference

Europe PubMed Central

11 November 2017

1

object named as

Carla Zoja

1 reference

Europe PubMed Central

11 November 2017

4

object named as

Sara Conti

1 reference

Europe PubMed Central

11 November 2017

Elena Gagliardini

3

object named as

Elena Gagliardini

1 reference

Europe PubMed Central

11 November 2017

publication date

18 August 2010

1 reference

Europe PubMed Central

11 November 2017

American Journal of Physiology - Renal Physiology

1 reference

Europe PubMed Central

11 November 2017

299

1 reference

Europe PubMed Central

11 November 2017

5

1 reference

Europe PubMed Central

11 November 2017

F1203-11

1 reference

Europe PubMed Central

11 November 2017

How does proteinuria cause progressive renal damage?

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Role of transforming growth factor beta in human disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Statins and blood pressure regulation.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

RhoA inactivation enhances endothelial barrier function

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Rosuvastatin protects against podocyte apoptosis in vitro

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

The statins--therapeutic diversity in renal disease?

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Statins: another class of antihypertensive agents?

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Transforming growth factor beta contributes to progressive diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Clinical practice. Nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Size and charge selectivity of the glomerular filter in early experimental diabetes in rats

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Role of remission clinics in the longitudinal treatment of CKD.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Proteinuria: Is the ONTARGET renal substudy actually off target?

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Progression, remission, regression of chronic renal diseases

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

The podocyte's response to injury: role in proteinuria and glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Molecular basis of glomerular permselectivity

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Podocyte number in normotensive type 1 diabetic patients with albuminuria

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator-Activated Receptor- Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00045.2010

21 January 2018

Identifiers

10.1152/AJPRENAL.00045.2010

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42933669&oldid=2087037151"